ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High Risk Patients With Hypertriglyceridemia and on Statin. The Primary Objective is to Evaluate the Effect of 4 g/Day AMR101 for Preventing the Occurrence of a First Major Cardiovascular Event. (REDUCE-IT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01492361
Recruitment Status : Active, not recruiting
First Posted : December 15, 2011
Last Update Posted : April 2, 2018
Sponsor:
Information provided by (Responsible Party):
Amarin Pharma Inc.